Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
The DOI matches its OpenAlex record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
This was a randomized, double-blind, placebo-controlled comparison of the efficacy and safety of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR). Outpatients with DSM-III-R major depression were randomly assigned to venlafaxine XR, 75 mg once daily, venlafaxine IR, 37.5 mg twice daily, or placebo for a maximum of 12 weeks. If the response was inadequate after 2 weeks of treatment, the dosage of venlafaxine XR or IR could be increased to 150 mg daily. The primary efficacy variables were the 21-item Hamilton Depression (HAM-D) Rating Scale total score and depressed mood item, the Montgomery-Asberg Rating Scale (MADRS) total scores, and the Clinical Global Impressions (CGI) severity scale. Two hundred seventy-eight patients were evaluated for efficacy. Venlafaxine XR was significantly superior (p < 0.05) to placebo beginning at week 2 for the HAM-D, week 3 for the MADRS, and week 4 for the CGI severity. Similarly, venlafaxine IR was significantly superior (p < 0.05) to placebo beginning at week 2 on the HAM-D total and depressed mood item, week 3 on the MADRS total, and week 6 on the CGI severity scales. Venlafaxine XR exhibited superiority (p < 0.05) over venlafaxine IR at week 12 for all efficacy variables. The most common treatment-emergent adverse event with venlafaxine XR was nausea. The incidence of nausea was highest during the first 2 weeks with a low likelihood of developing nausea thereafter. The results of this study indicate that venlafaxine XR is safe, effective, and well tolerated for the treatment of major depression at once-daily doses ranging from 75 to 150 mg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T., & Sigg, E. B. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90769-0 · Cited by 374
A Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression
CUNNINGHAM, L. A., BORISON, R. L., CARMAN, J. S., CHOUINARD, G., CROWDER, J. E., DIAMOND, B. I., FISCHER, D. E., & HEARST, E. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199404000-00003 · Cited by 159
Self-citationDieric, M., Ravizza, U., Realini, R., & Martin, A. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00292-8 · Cited by 152
Cited by
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269
Venlafaxine Extended-Release: A Review of its Use in the Management of Major Depression
Wellington, K., & Perry, C. M. (2001) · CNS Drugs · doi:10.2165/00023210-200115080-00007 · Cited by 263
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
“…Montgomery, 1995 Citalopram 226 1.76 (1.00–3.10) 9.5 (4.6 to >100) 1.37 Lauritzen et al., 1996 Paroxetine 58 6.33 (2.11–19.1) 1.8 (1.3–2.9) 0.56 Lauritzen et al., 1996 Imipramine 58 2.11 (1.16–3.86) 2.9 (1.7–9.7) 1.28 Cunningham, 1997 Venlafaxine 278 1.37 (0.99–1.90) 8.9 (4.3 to >100) 2.10…”
BackgroundInfluentialMontgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Metadata
- Authors
- Cunningham, L. A.
- Venue
- Annals of Clinical Psychiatry
- Published
- 1997-01-01
- Volume
- 9
- Issue
- 3
- Pages
- 157-164
- ISSN
- 1040-1237 (ISSN-L)
- OpenAlex
- W2110173591
- Cited by
- 78
- References
- 3
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. https://app.cochat.ai/papers/10.1023/a:1026277907818
- The paper
- Cunningham, L. A. (1997). Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Annals of Clinical Psychiatry. https://doi.org/10.1023/a%3A1026277907818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.